Platinum-based chemotherapy in childhood causes somatic mutations that accelerate liver cell ageing

A study published on 10 September 2026 and reported by Stat News describes findings that platinum-based chemotherapy agents — cisplatin and carboplatin, widely used in paediatric oncology — leave a distinctive somatic mutational signature in the liver cells of treated children. The mutation pattern makes treated children's liver cells resemble those of much older adults, a form of accelerated biological ageing at the cellular level.

The authors suggest this age-like mutational landscape may be associated with elevated long-term risk of secondary liver tumours in cancer survivors, though the reporting does not detail precise risk estimates or follow-up periods. The work adds to a growing literature on the late effects of childhood cancer treatment, characterising the molecular footprint of platinum compounds in a solid organ rather than in haematological cells where such signatures have been more extensively studied.

The study is relevant to paediatric oncologists, genetic counsellors supporting cancer survivors, and researchers working on treatment-related mutagenesis. It does not propose changes to clinical protocols. This item was also noted as a brief in Stat News's Readout digest (13 September); the primary research article and its authoring institution are not fully identified in the available reporting.